Search results for: 'hailing artificial intelligence'

15 May 2020  |  North America  |  Market Research

Artificial Intelligence in the Global Homes & Buildings Industry, Forecast to 2030

A Profound Understanding of Value-based Outcome is Crucial for the Mass Acceptance of Artificial Intelligence in the Homes & Buildings Industry

Infographics

×

Key Issues Addressed

Homes & buildings is a technology-driven industry that is witnessing innovation at a rapid pace, especially in Artificial Intelligence (AI) through machine learning and deep learning capabilities. Both leading and emerging participants in this space are strongly competing to secure a customer base and maximise their revenue potential. This study id...

25 Feb 2020  |  North America  |  Market Research

Artificial Intelligence in Enterprise Communications and Collaboration, Global, 2019

Assisted and Augmented Intelligence is Making Greater Headway in Workplaces

Infographics

×

Key Issues Addressed

This research study focuses on how AI is making inroads into the enterprise communications and collaboration arena. Subsequent to the dynamic technology shifts from on-premises enterprise communications to cloud-based communications services, the industry is further warming up to embrace AI and integrate it with multifarious communication channels...

This research service focuses on the US Department of Defense (DoD) artificial intelligence activities market. Representative programs, contracts, and market participants are included to form an overview picture of US DoD spending on this technology. An analysis of research, development, test, and evaluation (RDT&E); procurement; operations and ma...

This Frost & Sullivan research service focuses on US Department of Defense (DoD) artificial intelligence (AI) budget spending and contracts. Artificial intelligence tools are used across an array of DoD applications to enhance mission accomplishment and safety, including logistics, maintenance, healthcare, administration, networks, intelligence ana...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

Cities are evolving toward a more sustainable and efficient model. A focus area is reducing carbon emissions by adopting renewable energy sources like solar and wind power and promoting electric vehicles. In addition, there is a shift toward pedestrian-friendly urban design, with wider sidewalks, bike lanes, and increased green spaces. Cities want ...

06 Sep 2019  |  North America  |  Market Research

Global Ride Hailing Market, Forecast to 2030

Emerging Markets and Tier II and Tier III Cities are Redefining Opportunities; MaaS Integration is the Next Milestone

Infographics

×

Key Issues Addressed

The study aims to analyse and forecast the global ride hailing market outlook and technology trends for 2018. The ride hailing market has gone beyond providing taxis to be recognized as a platform for efficient mobility services. New opportunities are arising in the emerging markets of Latin America, Africa, and the Middle East while the developed ...

This research service offers an in-depth analysis of the current e-Hailing market and discusses the 2025 outlook. It delves into evolving business models, market consolidations and partnerships, regulatory reforms being undertaken by authorities, and advanced technology trends. The study also analyzes regional markets trends and captures growth pot...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...